Aurobindo Pharma Valuation and Intrinsic Value of Shares

thumbnail
Reading Time: 4 minutes


Source link | LinkedIn Profile | Twitter Profile

Aurobindo Pharma Valuation : About the Company

The company operates in the pharmaceutical business where market dominance is achieved through R&D, regulatory approvals, scale and distribution. Aurobindo Pharma is the 7th largest generic company by sales in the world and the 2nd largest Indian Pharmaceutical company in terms of revenue. It is also the 2nd largest generic Company by Rx dispensed in the US. This shows the sheer scale of operations which the company has along with a wide distribution across the globe. From here, we go ahead with Aurobindo Pharma Valuation and Intrinsic Value of its shares.

Read more here: Aurobindo Pharma Shares Fundamental Analysis 

Methodology Used:

Discounted cash flow (DCF) is a valuation method used to estimate the value of an investment based on its expected future cash flows. DCF analysis attempts to figure out the value of an investment today, based on projections of how much money it will generate in the future. The following step by step procedure is followed.

  1. Determining the Revenue Growth Rates
  2. Forecasting the Financial Statements
  3. Deriving the FCFF and FCFE
  4. Calculating the Terminal Value
  5. Calculating the Discount Rate
  6. Discounting the Cashflows
  7. Arriving at the Intrinsic Value of the Shares
Also Read on FinMedium:  Maruti Suzuki Fundamental Analysis and Future Outlook

You can also get the formula based DCF Excel Model used for this Analysis from below:



Step 1: Determining the Revenue Growth Rates

We arrive at the below table by using the past and expected future performance of both the company and the economy. This along with adjustments to changes in the management expectations, extraordinary events and other macro factors give the revenue growth rates for Aurobindo Pharma Valuation.

Financial Year Revenue Growth Rate
Year 1 10%
Year 2 14%
Year 3 15%
Year 4 14%
Year 5 15%
Revenue Growth Rates: Aurobindo Pharma Valuation

Step 2: Forecasting the Financial Statements

The financial statements are forecasted for a period of 5 years using the annual report data of the company. The assumptions used for forecasting are tabulated below. The Excel model is completely editable and can be adjusted for specific changes which may happen over a period of time.

Financial Statements Forecast : Aurobindo Pharma Valuation
Financial Statements Forecast : Aurobindo Pharma Valuation



Step 3: Deriving the FCFF and FCFE

Free cash flow to the firm (FCFF) represents the amount of cash flow from operations available for distribution after accounting for depreciation expenses, taxes, working capital, and investments. FCFF is a measurement of a company’s profitability after all expenses and reinvestments. It is given as follows.

Also Read on FinMedium:  Lumax Industries Company Analysis - The Automotive Lighting Manufacturer

Free cash flow to equity (FCFE) is a measure of how much cash is available to the equity shareholders of a company after all expenses, reinvestment, and debt are paid. FCFE is a measure of equity capital usage.

F/S Items (INR Millions) Mar-20 Mar-21 Mar-22 Mar-23 Mar-24
Free Cash Flow to Firm -10726 7837 15675 14031 16457
Free Cash Flow to Equity -2720 15863 42755 18874 27106
FCFF and FCFE values: Aurobindo Pharma Valuation

Step 4: Calculating the Terminal Value

Terminal value (TV) is the value of a business or project beyond the forecast period when future cash flows can be estimated. It assumes that a business will grow at a set growth rate forever after the forecast period. Terminal value often comprises a large percentage of the total assessed value.

Terminal Value Calculation Units INR Millions
Free Cash Flow to Firm 16457.19
Growth Rate 5.00%
Cost of Capital 11.35%
Terminal Value 271943.49
Terminal Value: Aurobindo Pharma Valuation

Step 5: Calculating the Discount Rate

DCF analysis helps assess the viability of a project or investment by calculating the present value of expected future cash flows using a discount rate. Here we use the Weighted average cost of capital (WACC) to discount the cash flow. The below table from the excel model shows the calculation of WACC for Aurobindo Pharma Valuation.

WACC Calculation for Aurobindo Pharma Valuation.
WACC Calculation for Aurobindo Pharma Valuation.



Also Read on FinMedium:  Detailed Analysis of FMCG Sector - Everything you need to know about this sector!

Step 6: Discounting the Cashflows

The WACC and the Cost of Equity for the company calculated in the above step are then used to discount the FCFF, FCFE and Terminal Value calculated in Step 3 and 4. In our case, we’ll only consider the FCFF based Intrinsic price of the shares as it represents the cash flow to all the suppliers of capital and not only to the equity shareholders. Thus we arrive at Present value of future FCFF for Aurobindo Pharma Valuation. (Units are INR Millions)

PV of FCFF and FCFE  for Aurobindo Pharma Valuation.
PV of FCFF and FCFE for Aurobindo Pharma Valuation.

Step 7: Arriving at the Intrinsic Value of the Shares

Dividing the PV of the FCFF and Terminal Value (the Value of the entire firm) by the number of outstanding shares we get the per share intrinsic value. We can compare this price with the current market price of the stock to get the Discount or Premium to its intrinsic price.

Aurobindo Pharma Valuation Units
PV in INR Million 185612
No of Shares Outstanding (In Million) 586
Intrinsic Value 316.74
Current Market Price of Share 782.00
Current Discount/Premium 147%
Intrinsic Value of the Shares: Aurobindo Pharma Valuation

Aurobindo Pharma Valuation and Intrinsic Share Price = INR 316.74

Subscribe via Email for our daily analysis on 200+ stocks!
Join our Telegram Channel.



Download the Excel Model from Here!

References: Investopedia
Our 150+ Stock Valuations
Our Stock ratings List
You can read more about the company on its website!
Investor Presentation.

(Note: All the research done by me is only for educational purposes and should not be seen as Investment recommendations. I am a Research analyst and not a SEBI registered Investment Advisor. My research completely reflects my personal opinions and not of my employers. Kindly do your own due diligence before Investing)



Source link | LinkedIn Profile | Twitter Profile

Every Wednesday and Saturday, we send Info-Graphic and FinMedium Weekly Digest newsletters to our 25000+ Subscribers.

Join Them Now!

Please Share :)
Billion Dollar Valuation
Billion Dollar Valuation shares thorough research into the Fundamentals of the businesses listed in India. With their insightful write-ups, they uncover a lot on the table.
Back To Top